Oncocyte Announces Oral Presentation of New Data on Its DetermaIO Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting Randomized clinical trial data from NeoTRIPaPDL1 study establishes

Announces Oral Presentation of New Data on Its DetermaIO Immunotherapy

Test at the European Society for Medical Oncology Annual Meeting

clinical trial data from NeoTRIPaPDL1 study establishes DetermaIO as a

biomarker of immunotherapy response

Investigators found DetermaIO outperformed 80 other immune related signatures in TNBC

Calif., September 20, 2021 - Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the

mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and

monitoring of cancer, today presented new data in an oral presentation at the European Society for Medical Oncology Congress (ESMO)

2021 evaluating DetermaIO as a biomarker for immune therapy response. The results demonstrated in a randomized clinical trial

setting that DetermaIO, a 27-gene precision diagnostic, is predictive of response to neoadjuvant immune checkpoint inhibitor

treatment of triple negative breast cancer (TNBC), and support the potential of DetermaIO to serve as a precision diagnostic for

this important class of novel therapies with expanding indications across tumor types.

on the trial results, Ron Andrews, Chief Executive Officer of Oncocyte, stated, "Demonstrating the utility of DetermaIO in the

rigorous setting of a randomized, therapeutic clinical trial is a landmark accomplishment for Oncocyte, and simply put, we are very enthusiastic

about the results. These data from a prestigious international clinical trial provide important confirmation of DetermaIO's capacity

to work as a precision diagnostic across the checkpoint inhibitor class of therapies which we believe can benefit both drug development

and add precision to patient treatment decisions. We are thrilled to add this new data to the compelling collection of studies that validate

the assay's utility in Lung, TNBC, and Bladder cancers, and across four approved immunotherapies - Keytruda , Opdivo ,

Tecentriq and Imfinzi - suggesting a potential pan-cancer and pan-immunotherapy utility in both primary

and metastatic settings. We look forward to advancing DetermaIO toward clinical launch in Q4, allowing us access to a US market estimated

at three billion dollars."

results and conclusions from the late breaking oral presentation titled, "Predictive value of gene-expression profiles (GEPs)

in the Neo TRIPaPDL1 trial", include:

Bianchini, M.D., Head of the Breast Cancer Group at the San Raffaele Scientific Institute, and trial investigator said, "Looking

at pathologic complete response in this prospectively, randomized Phase III trial, IO score demonstrated the ability to identify those

TNBC patients who benefitted the most from the addition of atezolizumab, and this was supported statistically by a significant test of

interaction. Notably, we assessed more than 80 immune-related signatures and none of them showed similar significant tests of interaction.

In addition, IO score was significantly more associated with pCR in atezolizumab arm than any other immune-related signatures. This observation

underscores the capability of the test to measure features across the tumor microenvironment, including those intrinsic to the tumor

(mesenchymal features) and extrinsic to the tumor such as immune infiltration."

Seitz, Head of Immune Oncology at Oncocyte, said, "One of the most common questions we get from experts in the immune oncology

field is how does DetermaIO compare to other immune related signatures. The additional research of Dr. Bianchini's group showed

that the IO score clearly distinguished itself from the numerous immune related signatures that were tested, a result that demonstrates

DetermaIO has a unique and pivotal role versus other tests in selecting patients for immunotherapy. This is an extremely important milestone,

where for the first time, by evaluating the tumor micro environment or TME, we have a precision diagnostic for immunotherapy that can

find the right treatment for the right patient with specificity for response."

Tuesday, September 28th, 2021 from 1-2PM EST, the Company will be hosting a Key Opinion Leader event with Dr. Bianchini and Priyanka

Sharma, M.D., Professor of Medicine at the University of Kansas Medical Center to discuss the unmet need for identifying patients with

triple-negative breast cancer (TNBC) who will respond to immunotherapy, with Dr. Bianchini highlighting the NeoTRIPaPDL1 randomized clinical

and Presentation Details:

type: Late-breaking abstract and oral presentation

Bianchini, G., et al.

and time: September 20, 2021, 17:30 CET

The NeoTRIPaPDL1 Study

NeoTRIPaPDL1 (NCT02620280) study is an international clinical trial comprising patients from seven countries across Europe

and Asia which randomized TNBC patients into two treatment arms: treatment with chemotherapy or treatment with chemotherapy in combination

with an immunotherapy. 241 patients with Stage I-III triple negative breast cancer were randomized to either receive immunotherapy plus

chemotherapy, or standard of care chemotherapy, prior to their surgery (the neoadjuvant setting). The trial investigators have previously

reported initial response data describing how the patient responded with the strongest response being no evidence of the tumor at the

time of surgery (pathologic complete response or pCR).

is a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform

critical decisions in the diagnosis, treatment, and monitoring of cancer. The Company, through its proprietary tests and pharmaceutical

services business, aims to help save lives by accelerating the diagnosis of cancer and advancing cancer care. The Company's tests

are designed to help provide clarity and confidence to physicians and their patients at every stage. DetermaRx identifies early-stage

lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy. DetermaIO , a gene

expression test currently used as a research-use only tool, assesses the tumor microenvironment to predict response to immunotherapies.

The Company's pipeline of tests in development also includes DetermaTx , which will assess the mutational status of a tumor;

blood-based monitoring test DetermaCNI , and long-term recurrence monitoring test DetermaMx . In addition, Oncocyte's

pharmaceutical services provide companies that are developing new cancer treatments a full suite of molecular testing services to support

the drug development process.

DetermaIOTM, DetermaTxTM, DetermaCNITM and DetermaMxTM are trademarks of Oncocyte Corporation.

Opdivo , Tecentriq and Imfinzi , are registered trademarks of Merck, Bristol Myers Squibb, Roche Genentech and AstraZeneca,

Forward Looking Statements. Oncocyte cautions you that this press release contains forward-looking statements. Any statements that

are not historical fact (including, but not limited to statements that contain words such as "will," "believes,"

"plans," "anticipates," "expects," "estimates," "may," and similar expressions)

are forward-looking statements. These statements include those pertaining to DetermaIO, including its potential to serve as a predictive

biomarker, and companion diagnostic, for immune therapy response prediction; its capacity to work as a companion diagnostic across the

checkpoint inhibitor class of therapies and both benefit drug development and add precision to patient treatment decisions; its potential

pan-cancer and pan-immunotherapy utility in both primary and metastatic settings; its expected clinical launch in Q4 2021; its potentially

unique and pivotal role versus other tests in selecting patients for immunotherapy; its potential to find the right treatment for the

right patient with specificity for response; and other statements about the future expectations, beliefs, goals, plans, or prospects

expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, the potential impact

of COVID-19 on Oncocyte or its subsidiaries' financial and operational results, risks inherent in the development and/or commercialization

of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte's

third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential

interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable

jurisdictions, and the need to obtain third party reimbursement for patients' use of any diagnostic tests Oncocyte or its subsidiaries

commercialize, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory

or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of

resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification.

Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements

should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the "Risk

Factors" and other cautionary statements found in Oncocyte's Securities and Exchange Commission filings, which are available

from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the

date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances

that exist after the date on which they were made, except as required by law.

LifeSci Advisors, LLC

Westwicke/ICR Healthcare PR